Guangdong Zhongsheng Pharmaceutical (002317) Fundamentals 2026 — P/E 78.5x, Revenue Analysis | SniperIQ
Guangdong Zhongsheng Pharmaceutical (002317) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥23.6B, trading at ¥27.80 on the SHZ. This SniperIQ fundamentals page covers Guangdong Zhongsheng Pharmaceutical's valuation (P/E 78.5x, P/B 5.6x), profitability (net margin 11.7%), revenue (¥2.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangdong Zhongsheng Pharmaceutical's market cap?
Guangdong Zhongsheng Pharmaceutical (002317) has a market capitalization of approximately ¥23.6B, trading at ¥27.80 on the SHZ. Market cap moves with the live share price.
What is Guangdong Zhongsheng Pharmaceutical's P/E ratio?
Guangdong Zhongsheng Pharmaceutical's trailing twelve-month P/E ratio is 78.5x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangdong Zhongsheng Pharmaceutical?
Guangdong Zhongsheng Pharmaceutical runs a net profit margin of 11.7%, a gross margin of 56.2%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangdong Zhongsheng Pharmaceutical generate?
Guangdong Zhongsheng Pharmaceutical reported revenue of ¥2.5B for fiscal year 2025, with net income of ¥276M and earnings per share (EPS) of 0.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangdong Zhongsheng Pharmaceutical pay a dividend?
Guangdong Zhongsheng Pharmaceutical offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangdong Zhongsheng Pharmaceutical financially healthy?
Guangdong Zhongsheng Pharmaceutical carries a debt-to-equity ratio of 0.07x and a current ratio of 4.14x, with a market beta of 0.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangdong Zhongsheng Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangdong Zhongsheng Pharmaceutical (002317) the key facts are: market cap ¥23.6B, P/E 78.5x, revenue ¥2.5B, 52-week range 16.2-34.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangdong Zhongsheng Pharmaceutical's full fundamentals live
Get Guangdong Zhongsheng Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.